Adjuvant Treatment of Early Non–Small Cell Lung Cancer in the Era of Immunotherapy - a podcast by ReachMD

CME credits: 0.50

Valid until: 30-03-2023

Claim your CME credit at https://reachmd.com/programs/cme/adjuvant-treatment-of-early-nonsmall-cell-lung-cancer-in-the-era-of-immunotherapy/13453/

Standard of care treatment for resectable early-stage NSCLC usually includes surgery in combination with neoadjuvant or adjuvant platinum-based chemotherapy; however, metastatic disease often develops. To lower the risk for recurrence, an area of active research is the use of immune checkpoint inhibitors as neoadjuvant and adjuvant therapy for early-stage NSCLC. Several immune checkpoint inhibitors are now being investigated in early-stage NSCLC, with promising results reported, suggesting a role for the use of neoadjuvant and adjuvant therapy with immune checkpoint inhibitors in early-stage NSCLC.

This educational activity will review the role of immunotherapy in early-stage NSCLC as adjuvant treatment, recent clinical data and the latest advances for immune checkpoint inhibitors as adjuvant treatment, and recent and ongoing clinical trials for adjuvant and neoadjuvant immunotherapy for the treatment of early-stage NSCLC so that clinicians are better able to integrate emerging data and new treatment options into clinical practice and inform, educate, and refer patients to clinical trials when appropriate.

Further episodes of ReachMD CME

Further podcasts by ReachMD

Website of ReachMD